Mexico Approves Medical Marijuana

Mexico’s Lower House of Congress recently passed a bill that legalizes the use of medical marijuana and scientific research. In particular, the bill classifies the controversial psychoactive component of marijuana — tetrahydrocannabinol or THC — as “therapeutic”. The move is akin to the U.S. Drug Enforcement Administration (DEA) rescheduling marijuana to a controlled substance that has therapeutic value for patients.

“The ruling eliminates the prohibition and criminalization of acts related to the medicinal use of marijuana and its scientific research, and those relating to the production and distribution of the plant for these purposes,” read a Congressional statement.

The bill will now be sent to President Enrique Pena Nieto who is expected to sign it into law. While Pena Nieto was once a vocal opponent to legalization, his viewpoint has shifted to view drug use as a “public health problem” where users should not be criminalized. He even proposed a bill last year that would have permitted Mexicans to carry up to an ounce of marijuana, but that measure has since stalled in Congress.

Who stands to gain from Cannabis Legalization in Mexico

Easton has partnered with BMV Medica SA de C.V. and together, own the exclusive distribution rights in Mexico and Latin America for patented women’s diagnostic and preventative care products from Common Sense Of Israel, along with two generic cancer drugs, Paclitaxel and Docetaxel from BioLyse Pharma of St. Catherine’s Ontario, Canada. Easton has also entered the e-liquids and e-vaporizer market through the acquisition of revenue generating company, iBliss, Inc.

Medica Sur SAB de CV is a Mexico-based company primarily engaged in the healthcare sector. The Company manages hospitals, emergency and diagnostic centers, medical laboratories, organ and blood banks, as well as an accommodation place. It provides medical services within various specializations, such as anatomic pathology, cardiology, gynecology and obstetrics, neonatology, neurophysiology, odontology, oncology, ophthalmology, orthopedics, otolaryngology, pediatrics, radiology and imaging, as well as radiosurgery. In addition, the Company offers medical tourism services and distributes drugs. It forms a part of Mayo Clinic Care Network. The Company operates through a range of subsidiaries, such as Corporacion de Atencion Medica SA de CV, El Portal Medico SA de CV, Servicios de Administracion Hospitalaria SA de CV and Telemed SA de CV. The Company is owned by Neuco SA de CV.

Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors and others industries such as medical marijuana. The company has ventured into the potentially lucrative medical marijuana industry through an investment into AMFIL Technologies and their groZONE anti-bacterial system. The company has the exclusive option to purchase up to 49% in a medical marijuana grow-op business/facility which has received a letter to build from Health Canada. The company’s gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of Cannabidiol extracts. Most recently Easton Pharmaceuticals Announces It Has Signed an LOI to Acquire An Interest in a 45 Acre Parcel for the Cultivation of Medical Marijuana in Toronto, Canada; Wholly Owned Subsidiary, iBliss in Birmingham’s UK Vaper Expo

Easton Pharmaceuticals recent headlines

TORONTO, ON–(Marketwired – May 24, 2017) – Easton Pharmaceuticals, Inc. (OTC PINK: EAPH) is pleased to announce that it has signed a Letter of Intent with Canadian Alliance Group to acquire an interest in their 45 acre fully owned parcel of land for the cultivation, production and sale of medical marijuana to the cannabis industry. Easton’s wholly owned subsidiary, iBliss Inc. is currently in Birmingham, UK for this weekend’s Vaper expo.

TORONTO, ON–(Marketwired – May 15, 2017) – Easton Pharmaceuticals, Inc. (OTC PINK: EAPH), announces that Easton / BMV Medica have formally accepted a proposal for the sub-licensing of product VS-Sense from a German based multi-national pharmaceutical company for Mexico, which includes an upfront cash payment to Easton / BMV and a royalty payment from all future sales.

TORONTO, ON–(Marketwired – May 2, 2017) – Easton Pharmaceuticals, Inc. (OTC: EAPH) announces it has signed an LOI for the acquisition of revenue producing, Israel based therapeutics company, Herbs of Kedem.

TORONTO, ON–(Marketwired – Apr 24, 2017) – Easton Pharmaceuticals, Inc. (OTC PINK: EAPH) is pleased to announce that it has signed a non-disclosure / confidentiality agreement with a Producer of Crop Protection, Fertilizer and Plant Wash Products Company based in Israel.

TORONTO, ON–(Marketwired – Apr 20, 2017) – Easton Pharmaceuticals, Inc. (OTC PINK: EAPH) is pleased to announce the execution of final agreement completing the 100% acquisition of revenue generating vaporizer and e-liquids manufacturer, iBliss Inc. and its holding company.

Please follow the link to read the orginal article: here